<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02659865</url>
  </required_header>
  <id_info>
    <org_study_id>16263</org_study_id>
    <secondary_id>I6F-MC-JJCE</secondary_id>
    <nct_id>NCT02659865</nct_id>
  </id_info>
  <brief_title>A Study of LY3039478 in Healthy Participants</brief_title>
  <official_title>A Single Ascending Dose Study for the Evaluation of the Effects of LY3039478 on the QT/Corrected QT Interval in Healthy Subjects and Pilot Relative Bioavailability</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate the safety of the study drug known as
      LY3039478 and evaluate two different formulations of LY3039478 in healthy participants. Part
      A has three periods. Either LY3039478 or placebo will be given once by mouth in each period.
      Part B has two periods. Participants will receive both formulations of LY3039478, by mouth,
      over the course of the study. Both parts of the study will also explore how much LY3039478
      gets into the bloodstream and how long it takes the body to get rid of it. Information about
      any side effects will also be collected. Participants may only enroll in one part. The study
      will last at least 33 days, not including screening. Screening must be performed up to 30
      days before enrollment.

      Part B was added by protocol amendment approved in April, 2016.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <completion_date type="Actual">June 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Time-Matched Difference in QTcF Interval Between LY3039478 (new formulation) Compared To Placebo at the Maximum Concentration (Cmax) of LY3039478</measure>
    <time_frame>Predose up to 48 hours after administration of study drug in each period</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics; Maximum Concentration (Cmax) of LY3039478 (new formulation)</measure>
    <time_frame>Predose up to 48 hours after administration of study drug in each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics; Area Under the Concentration Versus Time Curve (AUC) of LY3039478 (new formulation)</measure>
    <time_frame>Predose up to 48 hours after administration of study drug in each period</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics; Maximum Concentration (Cmax) of the 2 Formulations of LY3039478</measure>
    <time_frame>Predose up to 48 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics; Area Under the Concentration Versus Time Curve (AUC) for the 2 formulations of LY3039478</measure>
    <time_frame>Predose up to 48 hours after administration of study drug</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Part A: Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Single oral dose of placebo administered in one of three study periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part A: LY3039478 new formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escalating single oral dose of LY3039478 administered in two of three study periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY3039478 original formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of LY3039478 administered in one of two study periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: LY3039478 new formulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single oral dose of LY3039478 administered in one of two study periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part A: Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3039478 original formulation</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part B: LY3039478 original formulation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3039478 new formulation</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>Part A: LY3039478 new formulation</arm_group_label>
    <arm_group_label>Part B: LY3039478 new formulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Body mass index (BMI) of 18 to 32 kilogram per meter square (kg/mÂ²)

        Exclusion Criteria:

        - Known allergies to LY3039478, related compounds or any components of the formulation

          -  Have previously received LY3039478

          -  Smokers or who have stopped smoking less than 3 months ago
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance</name>
      <address>
        <city>Daytona Beach</city>
        <state>Florida</state>
        <zip>32117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 18, 2016</study_first_submitted>
  <study_first_submitted_qc>January 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2016</study_first_posted>
  <last_update_submitted>July 11, 2016</last_update_submitted>
  <last_update_submitted_qc>July 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

